(Q38053441)

27 August 2017

title

Chemotherapy: What is its role in meningioma? (English)

1 reference

27 August 2017

1 reference

W J Sherman

1

1 reference

27 August 2017

J J Raizer

series ordinal

2

1 reference

27 August 2017

language of work or name

1 reference

1 October 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1189-95; quiz 1196

1 reference

Intracranial meningiomas: diagnosis and treatment

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Chemotherapy for meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Temozolomide for treatment-resistant recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Methylation status of MGMT gene promoter in meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Salvage chemotherapy with CPT-11 for recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Adjuvant combined modality therapy for malignant meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Treatment of high risk or recurrent meningiomas with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Non-resectable slow-growing meningiomas treated by hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Exogenous hormone use and meningioma risk: what do we tell our patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Growth of a meningioma in a transsexual patient after estrogen-progestin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Meningioma pathology, genetics, and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Medical therapies for meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Inhibition of the growth of cultured human meningioma cells by recombinant interferon-α

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Aberrant signaling pathways in meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Expression and activation of epidermal growth factor receptors in meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Epidermal growth factor receptor expression in 72 meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Angiogenesis inhibitors: current strategies and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Role of radiation therapy in treating intracranial meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Meningioma: current treatment options and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.108

21 January 2018

Identifiers

DOI

10.1586/ERN.12.108

1 reference

27 August 2017

1 reference